Literature DB >> 8214701

Serum inorganic fluoride levels in mildly obese patients during and after sevoflurane anesthesia.

H Higuchi1, T Satoh, S Arimura, M Kanno, R Endoh.   

Abstract

Serum inorganic fluoride levels in obese versus control patients were compared during and after sevoflurane anesthesia. Mean serum inorganic fluoride levels in the obese group increased more rapidly and were significantly higher than in the control group at each sampling time (P < 0.01). The area under the curve of fluoride concentration, versus time up to 24 h and 48 h in the obese patients, was significantly greater than that in the nonobese patients (P < 0.001). Peak serum fluoride level in the obese patients was 51.7 +/- 2.5 mumol/L and exceeded 50 mumol/L for nearly 2 h. Our study showed that serum fluoride concentrations between mildly obese and nonobese patients differed during and after sevoflurane anesthesia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214701     DOI: 10.1213/00000539-199311000-00025

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

2.  Urinary sevoflurane and hexafluoro-isopropanol as biomarkers of low-level occupational exposure to sevoflurane.

Authors:  Antonio Accorsi; Barbara Morrone; Irene Domenichini; Simona Valenti; Giovanni Battista Raffi; Francesco Saverio Violante
Journal:  Int Arch Occup Environ Health       Date:  2005-04-30       Impact factor: 3.015

3.  Studies of the mechanism of nephrotoxicity of compound A in rats.

Authors:  J L Martin; L Kandel; M J Laster; R L Kerschmann; E I Eger
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

4.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

Review 5.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 6.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Higher chlorzoxazone clearance in obese children compared with nonobese peers.

Authors:  C Gade; K Dalhoff; T S Petersen; T Riis; C Schmeltz; E Chabanova; H R Christensen; G Mikus; J Burhenne; J C Holm; H Holst
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.